Cancer patients may not need lifelong immunotherapy, study suggests
NCT ID NCT04157985
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer progressed. The results help doctors decide the best length of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
- Could a simple scan and blood test outsmart liver cancer?
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?